ASH 2021 | Updates in treatment options for patients with AML
Rory Shallis, MD, Yale Cancer Center, West Haven, CT, shares his insights on treatment algorithms for patients with acute myeloid leukemia (AML), drawing focus on the decision-making process, including whether patients are eligible for intensive therapy, or would benefit from less intensive options. Dr Shallis then discusses the importance of considering disease biology when choosing treatment regimens, mentioning the impact of mutations such as FLT3, IDH1, and IDH2 in guiding this choice. To conclude, Dr Shallis mentions the importance of deciding whether a patient is eligible for allogeneic hematopoietic stem cell transplant (allo-HSCT) and how this may influence survival outcome. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
